NADPH oxidase (NOX) inhibitor therapy halts liver fibrosis in animal model of liver disease, say researchers. "While numerous studies have now demonstrated that advanced liver fibrosis in patients and in experimental rodent models is reversible, there is currently no effective therapy for patients," said principal investigator David A. Brenner, MD, vice chancellor for Health Sciences and dean of the School of Medicine at the University of California, San Diego. "This new study provides important validation of the role of NOX in liver fibrosis, and suggests that a NOX inhibitor could provide an effective treatment for this devastating disease." Most chronic liver diseases are associated with progressive fibrosis, which is triggered by the loss of liver cells and the activation of inadequate wound healing pathways. In addition, oxidative stress - which results from an inappropriate balance between the production and clearance of highly reactive molecules involved in cell signaling called reactive oxidative species (ROS) - leads to aberrant tissue repair in the liver. When the liver is injured - for example, through hepatitis or alcohol abuse -HSCs are activated to become myofibroblasts, cells which play a crucial role in wound healing and the body's response to inflammation by recruiting immune cells called macrophages to the injury site. This process, triggered by intracellular signalling pathways involving NOX, can result in an abundance of scarring and eventually result in the loss of organ function. By inhibiting NOX, the researchers theorized that myofibroblast activation and macrophage recruitment could be interrupted, preventing further fibrosis and potentially allowing regression of established fibrosis. They assessed the effectiveness of treatment with GKT137831 - a NOX1/4 inhibitor developed by Genkyotex SA of Geneva, Switzerland - in mouse models, and found that treatment with this NOX inhibitor suppressed ROS production, as well as NOX and fibrotic gene expression. "These data highlight the excellent pharmacological properties of GKT137831 and the broad potential for its use in fibrotic diseases,'' said Patrick Page, chief development officer at Genkyotex and contributor to the study. According to Brenner, the next steps include a clinical trial with this drug in patients with liver fibrosis. Source: Eurekalert << 8 Million Chickens Slaughtered Amid Bird Flu Outbreak 'Stroke Coach' Can Help Stroke Patients >> Recommended Reading Alcoholic Liver Disease Encyclopedia section of medindia gives general information about Alcoholic Liver Disease. READ MORE Quiz on Liver How many of us know that the liver is a vital organ the size of an American Football? To understand more about the liver and its functions spend a few minutes taking part in this ... READ MORE Liver Cancer Treatment - Animation Liver Cancer is the uncontrolled growth of cells in the liver. The present section provides a graphic description of the various forms of liver cancer treatment in addition to the latest techniques such as Chemoembolisation and Radio frequency ... READ MORE Cholesterol Regulator Plays Key Role in Development of Liver Fibrosis A key regulator of cholesterol and fat metabolism in the liver also plays an important role in the development of liver fibrosis, scientists have found. READ MORE Current Treatments for Liver Cancer Current Treatments for Liver Cancer (also known as hepatoma or hepatocellular carcinoma) can result in complete cure of the disease if it is detected early. READ MORE Drug Toxicity Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a drug, reaction to a drug or drug abuse. READ MORE Fatty Liver Disease: A Growing Health Problem in India Non alcoholic fatty liver disease (NAFLD) is the leading cause of liver dysfunction worldwide and is a rapidly growing health problem in India. READ MORE Hepatitis A Hepatitis A is the most benign of the hepatitis viruses and usually has no long term side effects. Hepatitis A vaccine is available that is 95% effective in preventing the disease. READ MORE Living Donor Liver Transplant: What Are the Risks? The risk of dying as a result of a living donor liver segment removal is between 0.2-2.0%. The risk of morbidity is anywhere between 1.3% (in highly experienced centers) to 60%. READ MORE Milk Thistle Milk Thistle is a resourceful natural plant which has many medicinal benefits. In herbal medication milk thistle is used in cases of liver diseases. READ MORE Wilson's Disease This is a rare inherited systemic disorder of copper metabolism, affecting the liver mainly before other organs. READ MORE Most Popular on Medindia Drug - Food Interactions Selfie Addiction Calculator Blood Donation - Recipients More News on: Drug ToxicityHepatitis ASignature Drug ToxicityLiverWilson's DiseaseMilk ThistleCurrent Treatments for Liver CancerFatty Liver Disease: A Growing Health Problem in IndiaLiving Donor Liver Transplant: What Are the Risks?